Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 14, 2005 - Issue 6
Submit an article Journal homepage
113
Views
20
CrossRef citations to date
0
Altmetric
Review

ADAM proteases, ErbB pathways and cancer

Bin-Bing S Zhou Drug Discovery Biology, Incyte Corporation, Experimental Station, Route 141 & Henry Clay Road, Building 400, Wilmington, DE 19880, USA. [email protected]
,
Jordan S Fridman Drug Discovery Biology, Incyte Corporation, Experimental Station, Route 141 & Henry Clay Road, Building 400, Wilmington, DE 19880, USA. [email protected]
,
Xiangdong Liu Drug Discovery Biology, Incyte Corporation, Experimental Station, Route 141 & Henry Clay Road, Building 400, Wilmington, DE 19880, USA. [email protected]
,
Steve M Friedman Drug Discovery Biology, Incyte Corporation, Experimental Station, Route 141 & Henry Clay Road, Building 400, Wilmington, DE 19880, USA. [email protected]
,
Robert C Newton Drug Discovery Biology, Incyte Corporation, Experimental Station, Route 141 & Henry Clay Road, Building 400, Wilmington, DE 19880, USA. [email protected]
&
Peggy A Scherle Drug Discovery Biology, Incyte Corporation, Experimental Station, Route 141 & Henry Clay Road, Building 400, Wilmington, DE 19880, USA. [email protected]
Pages 591-606 | Published online: 11 Jul 2005

References

  • BRINCKERHOFF CE, MATRISIAN LM: Matrix metalloproteinases: a tail of a frog that became a prince. Nat. Rev Mol. Cell Biol. (2002) 3(3):207–214.
  • WHITE JM: ADAMs: modulators of cell-cell and cell-matrix interactions. Curr. Opin. Cell Biol. (2003) 15(5):598–606.
  • SEALS DF, COURTNEIDGE SA: The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev. (2003) 17(1):7–30.
  • PORTERS, CLARK IM, KEVORKIAN L, EDWARDS DR: The ADAMTS metalloproteinases. Biochem. J. (2005) 386( 1):15–27.
  • BLOBEL CP, WOLFSBERG TG, TURCK CW et al.: A potential fusion peptide and an integrin ligand domain in a protein active in sperm-egg fusion. Nature (1992) 356(6366):248–252.
  • •Identification of the first ADAM family member.
  • WOLFSBERG TG, PRIMAKOFF P, MYLES DG, WHITE JM: ADAM, a novel family of membrane proteins containing A Disintegrin And Metalloprotease domain: multipotential functions in cell-cell and cell-matrix interactions. J. Cell. Biol. (1995) 131(2):275–278.
  • HOWARD L, LU X, MITCHELL S, GRIFFITHS S, GLYNN P: Molecular cloning of MADM: a catalytically active mammalian disintegrin-metalloprotease expressed in various cell types. Biochem. (1996) 317\(Part 0:45–50.
  • BLACK RA, RAUCH CT, KOZLOSKY CJ et al.: A metalloproteinase disintegrin that releases tumour-necrosis factor-a from cells. Nature (1997) 385(6618):729–733.
  • LOECHEL F, GILPIN BJ, ENGVALL E, ALBRECHTSEN R, WEWER UM: Human ADAM 12 (meltrin-a) is an active metalloprotease. J. Biol. Chem. (1998) 273(27):16993–16997.
  • ROGHANI M, BECHERER JD, MOSS ML et al.: Metalloprotease-disintegrin MDC9: intracellular maturation and catalytic activity. J. Biol. Chem. (1999) 274(6):3531–3540.
  • HOWARD L, ZHENG Y, HORROCKS M, MacIEWICZ RA, BLOBEL C: Catalytic activity of ADAM28. FEBS Lett. (2001) 498(1):82–86.
  • WEI P, ZHAO YG, ZHUANG L, RUBEN S, SANG QX: Expression and enzymatic activity of human disintegrin and metalloproteinase ADAM19/meltrin-f3. Biochem. Biophys. Res. Commun. (2001) 280(3):744–755.
  • SCHLOMANN U, WILDEBOER D, WEBSTER A et al.: The metalloprotease disintegrin ADAM8. Processing by autocatalysis is required for proteolytic activity and cell adhesion. J. Biol. Chem. (2002) 277(50):48210–48219.
  • FOURIE AM, COLES F, MORENO V, KARLSSON L: Catalytic activity of ADAM8, ADAM15, and MDC-L (ADAM28) on synthetic peptide substrates and in ectodomain cleavage of CD23. J. Biol. Chem. (2003) 278(33):30469–30477.
  • ZOU J, ZHU F, LIU J et al.: Catalytic activity of human ADAM33. j Biol. Chem. (2004) 279(10:9818–9830.
  • MASKOS K, FERNANDEZ-CATALAN C, HUBER R et al.: Crystal structure of the catalytic domain of human tumor necrosis factor-a-converting enzyme. Proc. Natl. Acad. Sci. USA (1998) 95(7):3408–3412.
  • STOCKER W, GRAMS F, BAUMANN U et al.: The metzincins--topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zinc-peptidases. Protein Sci. (1995) 4(5):823–840.
  • BLACK RA, DOEDENS JR, MAHIMKAR R et al.: Substrate specificity and inducibility of TACE (tumour necrosis factor-a converting enzyme) revisited: the Ala-Val preference, and induced intrinsic activity. Biochem. Soc. Symp. (2003) (70):39–52.
  • MOHAN MJ, SEATON T, MITCHELL J et al.: The tumor necrosis factor-a converting enzyme (TACE): a unique metalloproteinase with highly defined substrate selectivity. Biochemistry (2002) 41(30):9462–9469.
  • ZHENG Y, SAFTIG P, HARTMANN D, BLOBEL C: Evaluation of the contribution of different ADAMs to tumor necrosis factor-a (TNF-a) shedding and of the function of the TNF-a ectodomain in ensuring selective stimulated shedding by the TNF-a convertase (TACE/ADAM17). J. Biol. Chem. (2004) 279(40:42898–42906.
  • ANDERS A, GILBERT S, GARTEN W, POSTINA R, FAHRENHOLZ F: Regulation of the a-secretase ADAM10 by its prodomain and proprotein convertases. FASEB J. (2001) 15(10):1837–1839.
  • ENDRES K, ANDERS A, KOJRO E et al.: Tumor necrosis factor-a converting enzyme is processed by proprotein-convertases to its mature form which is degraded upon phorbol ester stimulation. Eur. Biochem. (2003) 270(11):2386–2393.
  • LAMMICH S, KOJRO E, POSTINA R et al.: Constitutive and regulated a-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc. Nati Acad. Sci. USA (1999) 96(7):3922–3927.
  • LUM L, REID MS, BLOBEL CP: Intracellular maturation of the mouse metalloprotease disintegrin MD C15. J. Biol. Chem. (1998) 273(40):26236–26247.
  • HOWARD L, MACIEWICZ RA, BLOBEL CP: Cloning and characterization of ADAM28: evidence for autocatalytic pro-domain removal and for cell surface localization of mature ADAM28. Biochem. J. (2000) 348(1):21–27.
  • SCHLONDORFF J, BECHERER JD, BLOBEL CP: Intracellular maturation and localization of the tumour necrosis factor-a convertase (TACE). Biochem. 1 (2000) 347\(Part 1):131–138.
  • HOUGAARD S, LOECHEL F, XU X et al.: Trafficking of human ADAM 12-L: retention in the trans-Golgi network. Biochem. Biophys. Res. Commun. (2000) 275(2):261–267.
  • KADOTA N, SUZUKI A, NAKAGAMI Y, IZUMI T, ENDO T: Endogenous meltrin-a is ubiquitously expressed and associated with the plasma membrane but exogenous meltrin-a is retained in the endoplasmic reticulum. I Biochem. (Tokyo) (2000) 128(6):941–949.
  • MOSS ML, WHITE JM, LAMBERT MH, ANDREWS RC: TACE and other ADAM proteases as targets for drug discovery. Drug Discov. Today (2001) 6(8):417–426.
  • BAX DV, MESSENT AJ, TART J et al.: Integrin a5f31 and ADAM-17 interact in vitro and co-localize in migrating HeLa cells. J. Biol. Chem. (2004) 279(20:22377–22386.
  • IBA K, ALBRECHTSEN R, GILPIN B et al.: The cysteine-rich domain of human ADAM12 supports cell adhesion through
  • •• syndecans and triggers signaling events that lead to 131 integrin-dependent cell spreading. J. Cell Biol. (2000) 149(5):1143–1156.
  • SMITH KM, GAULTIER A, COUSIN H et al.: The cysteine-rich domain regulates ADAM protease function in vivo. J. Cell Biol. (2002) 159(5):893–902.
  • REDDY P, SLACK JL, DAVIS R et al: Functional analysis of the domain structure of tumor necrosis factor-a converting enzyme. J. Biol. Chem. (2000) 275(19):14608–14614.
  • LEE MH, DODDS P, VERMA V et al: Tailoring tissue inhibitor of metalloproteinases-3 to overcome the weakening effects of the cysteine-rich domains of tumour necrosis factor-a converting enzyme. Biochem. J. (2003) 371(Pt 2):369–376.
  • SOLOMON KA, PESTI N, WU G, NEWTON RC: Cutting edge: a dominant negative form of TNF-a converting enzyme inhibits proTNF and TNFRII secretion. Immunol. (1999) 163(8):4105–4108.
  • MASSAGUE J, PANDIELLA A: Membrane-anchored growth factors. Ann. Rev .Biochem. (1993) 62:515–541.
  • ARRIBAS J, MASSAGUE J: Transforming growth factor-a and 13-amyloid precursor protein share a secretory mechanism. J. Cell Biol (1995) 128(3):433–441.
  • PANDIELLA A, MASSAGUE J: Cleavage of the membrane precursor for transforming growth factor a is a regulated process. Proc. Natl. Acad. Sci. USA (1991) 88(5):1726–1730.
  • ARRIBAS J, COODLY L, VOLLMER P et al.: Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors../. Biol. Chem. (1996) 271(19):11376–11382.
  • BREW K, DINAKARPANDIAN D, NAGASE H: Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta (2000) 1477(1-2):267–283.
  • MURPHY G, KNAUPER V, LEE MH et al.: Role of TIMPs (tissue inhibitors of metalloproteinases) in pericellular proteolysis: the specificity is in the detail. Biochem. Soc. Symp. (2003) (70):65–80.
  • AMOUR A, KNIGHT CG, ENGLISH WR et al.: The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs. FEBS Lett. (2002) 524(1-3):154–158.
  • MOHAMMED FE SMOOKLER DS, TAYLOR SE et al: Abnormal TNF activity in Timp3 / mice leads to chronic hepatic inflammation and failure of liver regeneration. Nat. Genet. (2004) 36(9):969–977.
  • CHO C, BUNCH DO, FAURE JE et al: Fertilization defects in sperm from mice lacking fertilin 0. Science (1998) 281(53801857-1859.
  • NISHIMURA H, CHO C, BRANCIFORTE DR, MYLES DG, PRIMAKOFF P: Analysis of loss of adhesive function in sperm lacking cyritestin or fertilin 3. Dev. Biol. (2001) 233(0:204–213.
  • WESKAMP G, CAI H, BRODIE TA et al: Mice lacking the metalloprotease-disintegrin MDC9 (ADAM9) have no evident major abnormalities during development or adult life. Mol. Cell Bio. (2002) 22(5):1537–1544.
  • PESCHON JJ, SLACK JL, REDDY P et al: An essential role for ectodomain shedding in mammalian development. Science (1998) 282(5392):1281–1284.
  • ••Knockout studies suggest ADAM17 iscrucial for the activation of EGFR during mouse development.
  • HARTMANN D, DE STROOPER B, SERNEELS L et al: The disintegrin/ metalloprotease ADAM 10 is essential for Notch signalling but not for a-secretase activity in fibroblasts. Hum. Mol Genet. (2002) 11(20:2615–2624.
  • HORIUCHI K, WESKAMP G, LUM L et al: Potential role for ADAM15 in pathological neovascularization in mice. Mol Cell Biol. (2003) 23(16):5614–5624.
  • ROEMER A, SCHWETTMANN L, JUNG M et al.: Increased mRNA expression of ADAMs in renal cell carcinoma and their association with clinical outcome. Oncol Rep. (2004) 11(2):529–536.
  • ISHIKAWA N, DAIGO Y, YASUI W et al: ADAM8 as a novel serological and histochemical marker for lung cancer. Clin. Cancer Res. (2004) 10(24):8363–8370.
  • LENDECKEL U, KOHL J, ARNDT M et al: Increased expression of ADAM family members in human breast cancer and breast cancer cell lines../. Cancer Res. Chi'. Oncol (2005) 131(1):41–48.
  • CARL-McGRATH S, LENDECKEL U, EBERT M, ROESSNER A, ROCKEN C: The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. Int. Oncol (2005) 26(1):17–24.
  • GRUTZMANN R, LUTTGES J, SIP OS B et al.: ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br. J. Cancer (2004) 90(5):1053–1058.
  • YAVARI R, ADIDA C, BRAY-WARD P, BRINES M, XU T: Human metalloprotease-disintegrin Kuzbanian regulates sympathoadrenal cell fate in development and neoplasia. Hum. Mol. Genet. (1998) 7(7):1161–1167.
  • YOSHIMURA T, TOMITA T, DIXON MF et al: ADAMs (a disintegrin and metalloproteinase) messenger RNA expression in Helicobacter pylori-infected, normal, and neoplastic gastric mucosa. J. Infect. Dis. (2002) 185(3):332–340.
  • WU E, CROUCHER PI, MCKIE N: Expression of members of the novel membrane linked metalloproteinase family ADAM in cells derived from a range of haematological malignancies. Biochem. Biophys. Res. Commun. (1997) 235(2):437–442.
  • KODAMA T, IKEDA E, OKADA A et al: ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor. Am. J. Pathol (2004) 165(5):1743–1753.
  • LE PABIC H, BONNIER D, WEWER UM et al: ADAM12 in human liver cancers: TGF-13-regulated expression in stellate cells is associated with matrix remodeling. Hepatology (2003) 37(5):1056–1066.
  • BORRELL-PAGES M, ROJO F, ALBANELL J, BASELGA J, ARRIBAS J: TACE is required for the activation of the EGFR by TGF-a in tumors. EMBO (2003) 22(5):1114–1124.
  • •Juxtacrine activation of the EGFR by TGF-a requires ligand cleavage and ADAM activity.
  • DING X, YANG LY, HUANG GW, WANG W, LU WQ: ADAM17 mRNA expression and pathological features of hepatocellular carcinoma. World J. Castroenterol (2004) 10(18):2735–2739.
  • KANG GH, SHIM YH, JUNG HY et al: CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res. (2001) 61(7):2847–2851.
  • WILD A, RAMASWAMY A, LANGER P et al.: Frequent methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene in pancreatic endocrine tumors. J. Clin. Endocrinol Metab. (2003) 88(3):1367–1373.
  • DULAIMI E, IBANEZ DE CACERES I, UZZO RG et al.: Promoter hypermethylation profile of kidney cancer. Clin. Cancer Res. (2004) 10(12 Part 1):3972–3979.
  • ANDREU T, BECKERS T, THOENES E, HILGARD P, VON MELCHNER H: Gene trapping identifies inhibitors of oncogenic transformation. The tissue inhibitor of metalloproteinases-3 (TIMP3) and collagen type I a-2 (COL1A2) are epidermal growth factor-regulated growth repressors. J. Biol. Chem. (1998) 273(22):13848–13854.
  • BLOBEL CP: ADAMs: key components in EGFR signalling and development. Nat. Rev Mol. Cell Biol. (2005) 6(1):32–43.
  • •Comprehensive review of the role of ADAMs in EGFR signalling.
  • YARDEN Y, SLIWKOWSKI MX: Untangling the ErbB signalling network. Nat. Rev Mol. Cell Biol. (2001) 2(2):127–137.
  • HARRIS RC, CHUNG E, COFFEY RJ: EGF receptor ligands. Exp. Cell Res. (2003) 284(1):2–13.
  • GRAUS-PORTA D, BEERLI RR, DALY JM, HYNES NE: ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. (1997) 16(7):1647–1655.
  • MOSESSON Y, YARDEN Y: Oncogenic growth factor receptors: implications for signal transduction therapy. Semi]. Cancer Biol. (2004) 14(4):262–270.
  • HOLBRO T, BEERLI RR, MAURER F et al.: The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. USA (2003) 100(15):8933–8938.
  • ALIMANDI M, ROMANO A, CURIA MC et al.: Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene (1995) 10(9):1813–1821.
  • NORMANNO N, BIANCO C, DE LUCA A, SALOMON DS: The role of EGF-related peptides in tumor growth. Front Biosci. (2001) 6:D685–707.
  • SAHIN U, WESKAMP G, KELLY K et al:Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. ./. Cell. Biol. (2004) 164(5):769–779.
  • •Systematic analysis of ADAMs on EGFR ligand shedding using different ADAM-deficient cells.
  • GEE JM, KNOWLDEN JM: ADAM metalloproteases and EGFR signalling. Breast Cancer Res. (2003) 5(5):223–224.
  • MERLOS-SUAREZ A, RUIZ-PAZ S, BASELGA J, ARRIBAS J: Metalloprotease-dependent protransforming growth factor-a ectodomain shedding in the absence of tumor necrosis factor-a-converting enzyme. ./. Biol. Chem. (2001) 276(50:48510–48517.
  • SUNNARBORG SW, HINKLE CL, STEVENSON M et al.: Tumor necrosis factor-a converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability. J. Biol. Chem. (2002) 277(15):12838–12845.
  • ZHAO J, CHEN H, PESCHON JJ et al: Pulmonary hypoplasia in mice lacking tumor necrosis factor-a converting enzyme indicates an indispensable role for cell surface protein shedding during embryonic lung branching morphogenesis. Dev. Biol. (2001) 232(1):204–218.
  • JACKSON LF, QIU TH, SUNNARBORG SW et al.: Defective valvulogenesis in HB-EGF and TACE-null mice is associated with aberrant BMP signaling. EMBO J. (2003) 22(10:2704–2716.
  • IWAMOTO R, YAMAZAKI S, ASAKURA M et al.: Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. Proc. Natl. Acad. Sci. USA (2003) 100(6):3221–3226.
  • SHI W, CHEN H, SUN J et al: TACE is required for fetal murine cardiac development and modeling. Dev. Biol. (2003) 261(2):371–380.
  • LUETTEKE NC, QIU TH, FENTON SE et al.: Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development (1999) 126(12):2739–2750.
  • IZUMI Y, HIRATA M, HASUWA H et al: A metalloprotease-disintegrin, MDC9/ meltrin-y/ADAM9 and PKC-8 are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. EMBO J. (1998) 17(24):7260–7272.
  • ASAKURA M, KITAKAZE M, TAKASHIMA S et al: Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat. Med. (2002) 8(1):35–40.
  • KURISAKI T, MASUDA A, SUDO K et al: Phenotypic analysis of Meltrin-a (ADAM12)-deficient mice: involvement of Meltrin-a in adipogenesis and myogenesis. Mol. Cell Biol. (2003) 23(1):55–61.
  • LEMJABBAR H, BASBAUM C: Platelet-activating factor receptor and ADAM10 mediate responses to Staphylococcus aureus in epithelial cells. Nat. Med. (2002) 8(1):41–46.
  • YAN Y, SHIRAKABE K, WERB Z: The metalloprotease Kuzbanian (ADAM10) mediates the transactivation of EGF receptor by G protein-coupled receptors. J. Cell Biol. (2002) 158(2):221–226.
  • BRACHMANN R, LINDQUIST PB, NAGASHIMA M et al.: Transmembrane TGF-a precursors activate EGF/TGF-a receptors. Cell (1989) 56(4):691–700.
  • WONG ST, WINCHELL LF, MCCUNE BK et al: The TGF-a precursor expressed on the cell surface binds to the EGF receptor on adjacent cells, leading to signal transduction. Cell (1989) 56(3):495–506.
  • GSCHWIND A, FISCHER OM, ULLRICH A: The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat. Rev Cancer. (2004) 4(5):361–370.
  • CHRISTIANSON TA, DOHERTY JK, LIN YJ et al: NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res. (1998) 58(22):5123–5129.
  • BASELGA J: Is circulating HER-2 more than just a tumor marker? Clin. Cancer Res. (2001a) 7(9):2605–2607.
  • UMEKITA Y, OHI Y, SAGARA Y, YOSHIDA H: Co-expression of epidermal growth factor receptor and transforming growth factor-a predicts worse prognosis in breast-cancer patients. Int. Cancer (2000) 89(6):484–487.
  • SALOMON DS, BRANDT R, CIARDIELLO F, NORMANNO N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev Oncol Hematol (1995) 19(3):183–232.
  • FONTANINI G, DE LAURENTIIS M, VIGNATI S et al.: Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin. Cancer Res. (1998) 4(1):241–249.
  • PRENZEL N, ZWICK E, DAUB H et a/.: EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature (1999) 402(6764):884–888.
  • GSCHWIND A, HARTS, FISCHER OM, ULLRICH A: TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. EMBO J. (2003) 22(10):2411–2421.
  • PAT R, SOREGHAN B, SZABO IL et al: Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat. Med. (2002) 8(3):289–293.
  • ROUDABUSH FL, PIERCE KL, MAUDSLEY S, KHAN KD, LUTTRELL LM: Transactivation of the EGF receptor mediates IGF-1-stimulated shc phosphorylation and ERK1/2 activation in COS-7 cells. J. Biol. Chem. (2000) 275(29):22583–22589.
  • BASELGA J, ALBANELL J, MOLINA MA, ARRIBAS J: Mechanism of action of trastuzumab and scientific update. Semin Oncol (2001) 28(5 Suppl. 16):4–11.
  • GREGORC V, CERESOLI GL, FLORIANI I et al.: Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer. Chi'. Cancer Res. (2004) 10(18 Part 1):6006–6012.
  • VECCHI M, CARPENTER G: Constitutive proteolysis of the ErbB-4 receptor tyrosine kinase by a unique, sequential mechanism. J. Cell Biol. (1997) 139(4):995–1003.
  • RIO C, BUXBAUM JD, PESCHON JJ, CORFAS G: Tumor necrosis factor-a-converting enzyme is required for cleavage of erbB4/HER4../. Biol. Chem. (2000) 275(14):10379–10387.
  • CODONY-SERVAT J, ALBANELL J, LOPEZ-TALAVERA JC, ARRIBAS J, BASELGA J: Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res. (1999) 59(6):1196–1201.
  • LIPTON A, ALI SM, LEITZEL K et al: Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J. Clin. Oncol (2002) 20(6):1467–1472.
  • BETHUNE-VOLTERS A, LABROQUERE M, GUEPRATTE S et al: Longitudinal changes in serum HER-2/neu oncoprotein levels in trastuzumab-treated metastatic breast cancer patients. Anticancer Res. (2004) 24(2C):1083–1089.
  • MOLINA MA, CODONY-SERVAT J, ALBANELL J et al.: Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. (2001) 61(12):4744–4749.
  • ALLENSPACH EJ, MAILLARD I, ASTER JC, PEAR WS: Notch signaling in cancer. Cancer Biol. Ther. (2002) 1(5):466–476.
  • MIYAMOTO Y, MAITRA A, GHOSH B et al: Notch mediates TGF a-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell (2003) 3(6):565–576.
  • FITZGERALD K, HARRINGTON A, LEDER P: Ras pathway signals are required for notch-mediated oncogenesis. Oncogene (2000) 19(37):4191–4198.
  • ZAGOURAS P, STIFANI S, BLAUMUELLER CM, CARCANGIU ML, ARTAVANIS-TSAKONAS S: Alterations in Notch signaling in neoplastic lesions of the human cervix. Proc. Natl. Acad. Sci. USA (1995) 92(14):6414–6418.
  • RAE FK, STEPHENSON SA, NICOL DL, CLEMENTS JA: Novel association of a diverse range of genes with renal cell carcinoma as identified by differential display. Int. J. Cancer (2000) 88(5):726–732.
  • ROOKE J, PAN D, XU T, RUBIN GM: KUZ, a conserved metalloprotease-disintegrin protein with two roles in Drosophila neurogenesis. Science (1996) 273(5279):1227–1231.
  • WEN C, METZSTEIN MM, GREENWALD I: SUP-17, a Caenorhabditis elegans ADAM protein related to Drosophila KUZBANIAN, and its role in LIN-12/NOTCH signalling. Development (1997) 124(23):4759–4767.
  • MUMM JS, SCHROETER EH, SAXENA MT et al.: A ligand-induced extracellular cleavage regulates y-secretase-like proteolytic activation of Notch1. Mol. Cell (2000) 5(2):197–206.
  • BROU C, LOGEAT F, GUPTA N et al.: A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol. Cell (2000) 5(2):207–216.
  • MARSHMAN E, STREULI CH: Insulin-like growth factors and insulin-like growth factor binding proteins in mammary gland function. Breast Cancer Res. (2002) 4(6):231–239.
  • MOHAN S, THOMPSON GR, AMAARYG et al: ADAM-9 is an insulin-like growth factor binding protein-5 protease produced and secreted by human osteoblasts. Biochemistry (2002) 41(51):15394–15403.
  • SHI Z, XU W, LOECHEL F, WEWER UM, MURPHY LJ: ADAM 12, a disintegrin metalloprotease, interacts with insulin-like growth factor-binding protein-3. J. Biol. Chem. (2000) 275(24):18574–18580.
  • MOCHIZUKI S, SHIMODA M, SHIOMI T, FUJII Y, OKADA Y: ADAM28 is activated by MMP-7 (matrilysin-1) and cleaves insulin-like growth factor binding protein-3. Biochem. Biophys. Res. Commun. (2004) 315(1):79–84.
  • LOECHEL F, FOX JW, MURPHY G, ALBRECHTSEN R, WEWER UM: ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem. Biophys. Res. Commun. (2000) 278(3):511–515.
  • HANKINSON SE, WILLETT WC, COLDITZ GA et al.: Circulating concentrations of insulin-like growth factor-land risk of breast cancer. Lancet (1998) 351(9113):1393–1396.
  • BRUNING PF, VAN DOORN J, BONFRER JM et al.: Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer. Int. J. Cancer (1995) 62(3):266–270.
  • KREBS LT, XUE Y, NORTON CR et al.: Notch signaling is essential for vascular morphogenesis in mice. Genes Dev. (2000) 14(11):1343–1352.
  • HALL H, DJONOV V, EHRBAR M, HOECHLI M, HUBBELL JA: Heterophilic interactions between cell adhesion molecule Li and avf33-integrin induce HUVEC process extension in vitro and angiogenesis in vivo. Angiogenesis (2004) 7(3):213–223.
  • MECHTERSHEIMER S, GUTWEIN P, AGMON-LEVIN N et al.: Ectodomain shedding of Li adhesion molecule promotes cell migration by autocrine binding to integrins. J. Cell Biol. (2001) 155(4):661–673.
  • BEERS, OLESZEWSKI M, GUTWEIN P, GEIGER C, ALTEVOGT P: Metalloproteinase-mediated release of the ectodomain of Li adhesion molecule. ./. Cell Sci. (1999) 112 (Pt 10:2667–2675.
  • GUTWEIN P, OLESZEWSKI M, MECHTERSHEIMER S et al.: Role of Src kinases in the ADAM-mediated release of Li adhesion molecule from human tumor cells. J. Biol. Chem (2000) 275(20):15490–15497.
  • FOGEL M, GUTWEIN P, MECHTERSHEIMER S et al.: Li expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet (2003) 362(9387):869–875.
  • TEDDER TF, STEEBER DA, CHEN A, ENGEL P: The selectins: vascular adhesion molecules. FASEB J. (1995) 9(10):866–873.
  • NAKAMURA H, SUENAGA N, TANIWAKI K et al.: Constitutive and induced CD44 shedding by ADAM-like proteases and membrane-type 1 matrix metalloproteinase. Cancer Res. (2004) 64(3):876–882.
  • NAGANO 0, MURAKAMI D, HARTMANN D et al.: Cell-matrix interaction via CD44 is independently regulated by different metalloproteinases activated in response to extracellular Ca(2+) influx and PKC activation. J. Cell Biol. (2004) 165(6):893–902.
  • NATH D, WILLIAMSON NJ, JARVIS R, MURPHY G: Shedding of c-Met is regulated by crosstalk between a G-protein coupled receptor and the EGF receptor and is mediated by a TIMP-3 sensitive metalloproteinase. J. Cell Sri. (2001) 114\(Part 6):1213–1220.
  • MILLICHIP MI, DALLAS DJ, WU E, DALE S, McKIE N: The metallo-disintegrin ADAM10 (MADM) from bovine kidney has type IV collagenase activity in vitro. Biochem. Biophys. Res. Commun. (1998) 245(2):594–598.
  • MARTIN J, EYNSTONE LV, DAVIES M, WILLIAMS JD, STEADMAN R: The role of ADAM 15 in glomerular mesangial cell migration. J. Biol. Chem. (2002) 277(37):33683–33689.
  • BASELGA J: Clinical trials of Herceptin (trastuzumab). Eur. J. Cancer (2001b) 37\(Suppl. 1):518–24.
  • GRAHAM J, MUHSIN M, KIRKPATRICK P: Cetuximab. Nat. Rev Drug Discov. (2004) 3(7):549–550.
  • HERBST RS, FUKUOKA M, BASELGA J: Gefitinib-a novel targeted approach to treating cancer. Nat. Rev Cancer (2004) 4(12):956–965.
  • PAEZ JG, JANNE PA, LEE JC et al.: EGFR Mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004)
  • LYNCH TJ, BELL DW, SORDELLA R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to Gefitinib. N Engl. J. Med. (2004)
  • PAO W, MILLER V, ZAKOWSKI M et al.: EGF receptor gene mutations are common in lung cancers from "never smokers'' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad Sci. USA (2004) 101(36):13306–13311.
  • MATAR P, ROJO F, CASSIA R et al.: Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD-1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clia Cancer Res. (2004) 10(19):6487–6501.
  • HUANG S, ARMSTRONG EA, BENAVENTE S, CHINNAIYAN P, HARARI PM: Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res. (2004) 64(15):5355–5362.
  • NORMANNO N, CAMPIGLIO M, DE LA et al.: Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann. Oncol. (2002) 13(1):65–72.
  • MOTOYAMA AB, HYNES NE, LANE HA: The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res. (2002) 62(11):3151–3158.
  • KAKIUCHI S, DAIGO Y, ISHIKAWA N et al.: Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum. Moi Genet. (2004) 13(24)3029–3043.
  • LU Y, ZI X, ZHAO Y, MASCARENHAS D, POLLAK M: Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J. Nati Cancer Inst. (2001) 93(24):1852–1857.
  • LU Y, ZI X, POLLAK M: Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int. Cancer (2004) 108(3):334–341.
  • AHONEN M, POUKKULA M, BAKER AH et al.: Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors. Oncogene (2003) 22(14):2121–2134.
  • BAKER AH, ZALTSMAN AB, GEORGE SJ, NEWBY AC: Divergent effects of tissue inhibitor of metalloproteinase- 1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. Clia Invest. (1998) 101(6):1478–1487.
  • BIAN J, WANG Y, SMITH MR et al.: Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP)-3. Carcinogenesis (1996) 17(9):1805–1811.
  • QI JH, EBRAHEM Q, MOORE N et al.: A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat. Med. (2003) 9(4):407–415.
  • VAN DER LAAN WH, QUAX PH, SEEMAYER CA et al.: Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of TIMP-1 and TIMP-3. Gene Ther. (2003) 10(3):234–242.
  • DONG J, OPRESKO LK, DEMPSEY PJ et al.: Metalloprotease-mediated ligand release regulates autocrine signaling through the epidermal growth factor receptor. Proc. Natl. Acad. Sci. USA (1999)96(1 1) :6235–6240.
  • OCHAROENRAT P, RHYS-EVANS PH, MODJTAHEDI H, ECCLES SA: The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma. Oral Omni (2002) 38(7):627–640.
  • COUSSENS LM, FINGLETON B, MATRISIAN LM: Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (2002) 295(5564):2387–2392.
  • HOLMBECK K, BIANCO P, CATERINA J et al: MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell (1999) 99(0:81–92.
  • BARLAAM B, BIRD TG, LAMBERT-VAN DER BREMPT C et al: New a-substituted succinate-based hydroxamic acids as TNF-a convertase inhibitors. J. Med. Chem. (1999) 42(23):4890–4908.
  • WOJTOWICZ-PRAGA S, TORRI J, JOHNSON M et al: Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. Omni (1998) 16(6):2150–2156.
  • HANDE KR, COLLIER M, PARADISO L et al: Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor. Clin. Cancer Res. (2004) 10(3):909–915.

Websites

  • http://www.people.virginia.edub-jw7g/ Table_of the_ADAMs.html Table of ADAMs.
  • www.iddb3.com IDdb drug database.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.